Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
Several technologies for hemoglobinopathies are being transferred to commercial partners
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
Takeda will seek an external partner to leverage its cell therapy platform technologies
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
Subscribe To Our Newsletter & Stay Updated
